CA2016699C - Lytic agents and uses thereof - Google PatentsLytic agents and uses thereof
- Publication number
- CA2016699C CA2016699C CA 2016699 CA2016699A CA2016699C CA 2016699 C CA2016699 C CA 2016699C CA 2016699 CA2016699 CA 2016699 CA 2016699 A CA2016699 A CA 2016699A CA 2016699 C CA2016699 C CA 2016699C
- Grant status
- Patent type
- Prior art keywords
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-' 1 a P6t701 1.YT~C pIGFIdTS ~IIdD tT~E~ EOF
This invention relates generally to reagents and methods useful in flow cytometry measurement of red and white blood cell populations, and more specifically, to the use of a lytic agent containing an aromatic oxyethanol acting as a red blood ce~.l lyse and white blood cell sheath and simultaneously as an antibacteriostat, enabling a five subpopulation digferentiatioi~ of leukocytes in an automated instrument.
The examination of the peripheral blood is an important aspect in evaluating the health of the individual. ~n important parameter within this examination is the differential white cell (or leukocyte) count. This test is presently performed in one of three ways. The most traditional method involves the preparation of a blood smear which is then stained via the Romanowsky method. This stain differentially colors the different constituents of whole blood. A technologist can enumerate the various leukocyte classes, typically
- 2 - P6001 neutrophils, lymphocytes, monocytes, eosinophils, and basophils by microscopic examination of the stained blood smear. As this manual differentiation is very labour intensive,, substantial research and development effort has been expended to obtain an automated procedure for the examination of blood samples.
Recently multi-subpopulation leukocyte differential analysis has been routinely obtained with automated microscopes. These automated microscopes include the *Hematrak series of products manufactured by Geometric Data (Wayne, Pennsylvania) and the *Diff 350 and 400 produced by Coulter Biomedical (Concord, Massachusetts). When these instruments are presented with a Romanowsky stained blood smear, using an image analysing computer, these instruments can locate and classify white blood cells using visual classification criteria similar to those used by the human technician. These criteria typically include nuclear and cytoplasmic optical density, colour, shape and texture.
Another approach to automation of leukocyte differential involves the use of flow cytometry. In this procedure, blood cells in suspension are passed through a transducer and the cells are classified on the basis of some measurable parameter such as light absorption, light scatter or electrical impedance. The advantages of these flow cytometry systems compared to microscope-based systems include relatively high sample throughput and the ability to count larger number of cells per sample thereby reducing sampling noise. Commercial clinical flow cytometers have been limited, thus far, to three leukocyte subpopulation differential. Leukocytes are classified in subpopulations called granulocytes, monocytes and lymphocytes. The current three part differential * denotes trade mark
- 3 - P6001 instruments are based on either measurement of light scatter or electrical impedance. Light scatter instruments such as *ELT 1500 of Ortho Instruments (Westwood, Massachusetts) classify white blood cell subpopulations on the basis of their light scattering characteristics measured at two different angles, typically termed "low" and "orthogonal". Electrical impedance instruments such as the S+ series of Coulter Electronics (Hialeah, Florida) and *Cell ~yn 2000 of ' Sequoia-Turner Corporation, (Mountain View, California), classify leukocytes based on their volume following exposure to a volume modifying reagent.
Until recently, the only commercial clinical flow cytometry instruments capable of obtaining a five-subpopulation leukocyte differential were the *H-6000 and H*1 of Technicon Instruments (Tarrytown, New York).
These instruments classify leukocytes by measuring light scatter and absorption after elaborate cytochemical staining of the blood cells. Since this staining process is relatively slow, the throughput of these instruments is compromised.
*Celi-Dyn 3000 of Sequoia-Turner Corp. (Mountain View, California) performs a conventional five subpopulation differential based only upon light scattering characteristics of unstained leukocyte cells.
Since inherently slow cytochemical staining is not used, the sample.throughput of this instrument is kept extremely high. The advances made possible by*Cell-Dya 3000 are largely the result of the combination of two innovations, namely measurement of depolarized orthogonal light scatter and the lytic agent of the present invention, enabling better resolution of lymphocytes and monocytes to obtain a five-subpopulation leukocyte differential analysis.
* denotes trade mark ~,~a~~i~~
- 4 - ~'6b01 In commercially available automated instruments using flow cytometry, the leukocyte classification and differentiation is obtained either by light scatter or by electrical impedance related to cell size. In either type of instrument, the red blood cells in the whole blood sample must be lysed to release the hemoglobin. In electrical impedance measurement-based systems, quaternary ammonium-salt-based lysing agents have been used. These electrical impedance systems have an adequate response time which substantially nullifies the lytic effect of the lysing agent of the leukocytes. In light scattering measurement-based systems, the adverse effect of the red blood cell lysing agent upon the light scattering characteristics of the white blood cells is more severe, and thus more demanding from a design perspective. Lytic agents (used herein interchangeably with "lysing agents") must rapidly lyse red blood cells while simultaneously providing a window in which white blood cell light scattering characteristics are essentially undisturbed.
These criteria are typically met using a lytic agent with an alkaline pH, since the range of lysis of both red blood cells and white blood cells increases with pH. The widely used ammonium chloride/potassium bicarbonate/diNaEOTA lysis solution has a pH of 7. 27.4, but typically takes 5-10 minutes to completely lyse red blood cells. Lytic agents such as Ortho Instruments, °'Lyse Right" have a pH of 8.5 and require several seconds to effect complete lysis of red blood cells, but will adversely affect the light scattering characteristics of white blood cells within a period of a minute or so. When the pH is raised much above this, or lowered below about 3, lytic agents are obtained that iyse both red blood cells and white blood cells almost instantaneously.
- 5 - 7Pfi001 Therefore, ft is an object of the invention to provide a lytic agent which adequately lyses red blood cells while preserving the light scattering characteristics of the white blood cells for the period of time adequate to obtain subpopulation differentiation.
It is a further object of this invention to provide a lytic agent which enables the enumeration of five leukocyte subpopulations, identified as neutrophils, lymphocytes, monocytes, eosinophils and basophils, in a flow cytometry, light-scattering system.
It is another object of this invention to provide a lytic agent which has a commercially acceptable shelf life.
These and further objects of the present invention will become apparent to those of skill in the art with reference to the specification and figures.
Thus, according to the invention, there is provided a lytic agent, of use for example in flow cytometry, comprising an aqueous solution of an aromatic oxyethanol, an organic buffer with pK at or near ~.5, and a non-ionic detergent.
The flow cytometry lytic agent of the present invention enables a five part differential enumeration of leukocytes into subpopulations identified as neutrophils, lymphocytes, monocytes, eosinophils and basophils. The lytic agent consists of an aromatic oxyethanol, an organic buffer, having pK at or near 8.5, which serves to provide pH buffering capacity and to increase electrical conductivity of the lytic agent, and a non-ionic detergent component. The aromatic oxyethanol is preferably
- 6 - P6001 2-phenoxyethanol. The organic buffer is selected from the group consisting of *TRIS/HC1, boric acid, glycyl/glycine and *B=CINrs. The non-ionic detergent is selected from the group consisting of *Triton-X 100, *Troton X-114, polyoxyethylene or saccharide-derived detergents. The preferred lytic agent consists essentially of 2-phenoxyethanol at a concentration between 20 mM and 80 mM, TRIS/HC1 buffer and*Triton-x 100.
The method of the present invention provides the lytic agent as described above in combination with a diluted whole blood sample. After the addition of the lytic agent to the diluted whole blood sample, the red and white blood cells are intersected with a focused laser beam. Four light scattering parameters are then measured at 0 degrees, l0 degrees, 90 degrees, and 90 degrees depolarized. These measured parameters are thereafter resolved to obtain a five part subpopulation differential enumerating the neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
The invention will now be described with reference to the accompanying figures in which;
Figure 1 is a perspective view of the *Cell-Dyn 3000 automated hematology instrument which practices the present invention.
Figure 2 is a schematic representation of the principle of impedance cell counting and size.
Figure 3 is a cross sectional, schematic view of the optical transducer of the*Cell-Dyn 3000 instrument.
* denotes trade mark
- 7 - P6001 Figure 4 is a schematic representation of the optical bench of the*Cell-Dyn 3000 instrument.
Figure 5 is' a white blood cell scattergram for the whole blood sample described in Example 1.
Figure 6 is a rnihite blood cell scattergram for the whole blood sample described in 8xample 2.
Figure 7 is a White blood cell scattergram for the whole blood sample described in Example 3.
Figure 8 is a white blood cell scattergram for the whole blood sample described in Example 4.
In the preferred embodiment, the lytic agent comprises an aqueous solution of *Triton-X 100, 2-phenoxyethanol, and TRIS/HC1 buffer. Whole blood is mixed with an excess of this lytic reagent, typically a 50-fold excess. Lysis of the red blood cells occurs instantly due to the combination of osmotic shock, the action of the non-ionic detergent and pH of about 8.5.
The 2-phenoxyethanol in the lytic agent serves two functions. Firstly, it functions as a leukoprotective reagent to retard lysis of lymphocytes, enabling detection of the subpopulations prior to substantial adverse effects on the white blood cells' optical properties caused by the lytic agent. Secondly, 2-phenoxyethanol functions in its more common role as an antimicrobial, allowing the reagent to remain free of microbial contamination for at least one year after preparation. The TRIS/HCl, a buffer commonly used in biochemical solutions, in addition to providing pH
buffering capacity, serves to increase the conductivity of the solution so that its presence in the reagent reservoir of the instrument may be readily detected using a pair of electrodes. The*Tritoa-x 100 serves as a wetting agent, reducing the hamg up of air bubbles in the *Cell-nyn 3000 tubing and optical transducer.
* denotes trade mark
- 8 - P6001 The optimal formulation of the lytic agent is given below:
2-phenoxyethanol (a liquid at 25°C) ......... 750 mL
TRIS/HCl buffer, pH 8.5 (500 mM TRIS
titrated to pH 8.5 with 1 M HC1) ............ 1500 mL
0.5% (vol/vol) aqueous Triton X-100 ......... 100 mL
Deionized water to .......................... 100 L
In the optimised formulation, 2-phenoxyethanol is present at a concentration of about 41 mM, although a useful range of concentrations exist between 20 and 80 mM. The pH of the TRIS buffer may be decreased to pH 8.1 without significant effects on its performance. If increased above pH 9.0, partial destruction of white blood cells can occur. The presence of trace amounts, up to about 5%
(vol./vol.) of *Tritoa-X 100 or a similar non-ionic detergent, prevents problems caused by inadequate lysis in specimens typically regarded as difficult to lyse. These include whole blood samples from patients with hemoglobinopathies and from those with elevated red blood cell counts.
Other organic buffers can be substituted for TRIS/HC1. Among those with pR at or near 8.5, boric acid, glycyl/glycine and *ezC=~(available through CalBiochem) can be used in the lytic agent of the present invention.
With respect to the non-ionic detergent component of the lytic agent,*Tritoa x-114 can be used. Other hydrophilic detergents can be selected from those having polyoxyethylene or saccharide head groups.
The optimised formulation enables a five-part leukocyte differential to be obtained, using the light scattering properties of these cells. The *Cell-Dya3000 * denotes trade mark
9 - P6001 measures four light scattering parameters on each leukocyte as it intersects a focused laser beam. These parameters are:
(1) ''0 degrees light scatter'° which is actually light scattered at about 1-3 degrees with respect to the laser beam.
(2) '°10 degree light scatter'° which is actually light scattered at about 3-10 degrees with respect to the laser beam.
(3) °°90 degree light scatter°' which is light scattered orthogonally to the laser beam.
(4) °°90 degree depolarized light scatter" which is light scattered orthogonally to the laser beam, which by interaction with white cells is no longer vertically polarised.
We found that 2-phenoxyethanol was an effective leukoprotective agent as well as its more common use as an antimicrobial. 7Cn addition, 2-phenoxyethanol produced much better resolution of lymphocytes and monocytes by flow cytometry light scattering methods. In fact, with 2-phenoxyethanol a four part differential, ie lymphocytes, basophils, monocytes, neutrophils & eosinophils, can be obtained simply on the basis of low angle and orthogonal light scatter. Prior to this, only a three part leukocyte differential had proved possible using these two parameters. This phemomenon may be observed in certain instruments, produced by Ortho Diagnostic systems, Inc.
such as the ELT 1500.
- 10 - P6001 Although a simple aqueous solution of 2-phenoxyethanol in water is an effective lytic agent, the electrical conductivity of this reagent is too low if the presence of the lytic reagent in instrument reservoirs is to be detected electrically. We therefore incorporated a TRIS/HC1 buffer into our lytic agent to raise the conductivity of the lytic reagent solution and to stabilise pH. To minimise the incidents of problems due to partial white cell lysis, we have also incorporated trace amounts of a non-ionic buffer, *Triton-x 100 into our formulation. This chemical also increases the wetting properties of the lytic agent in the reagent lines.
Turning now to the*Cell-Dya 3000 instrument 10 itself (see Figure 1), a pair of transducers are used for cell measurement. White blood cells are measured by light scatter. In this channel, fluid metering is via syringe pump. Red blood cells and platelets are measured by their electronic impedance. In this channel a volumetric metering tube is used.
*C$LL-DYN 3000 operations are controlled by three microprocessors which monitor system status, store data, run QC programs, flag abnormal data and perform diagnostic checks.
The user can select any of eight modes using screen 12 labels. Any mode may be obtained using either the membrane keyboard, or full PC keyboard. The primary operating modes are as follows:
SETUP - to set up or revise system operation RUN - to run specimens and controls DATA LOG - to review or print stored data QC - to review or print data in control or * denotes trade mark
- 11 - P6001 replicate files CALIBRATION - to review or run user calibration DIAGNOSTICS - to perform system checks for troubleshooting HELP - to assist user in the operation of the instrument SPECIAL
PROTOCOLS - to run special procedures such as cleaning the sample valve or priming the sample lines For ease to transport, the *CELL-DYN 3000 is divided into two modules. The main module 14 is constructed so that mixing chambers, valves, pumps, hemoglobin flow cell and the impedance transducer are all readily accessible at the front of the instrument 10. The back of the instrument contains two microprocessors. The upper compartment contains an optical bench on which are mounted lenses, laser, photodetectors and a fused-silica flow cell. See Figure 4. The second module 16 comprises the video monitor, PC and keyboard.
The *CELL-DYN 3000 uses three transducers to collect data on blood cells and hemoglobin concentration. These are designated the impedance transducer, the optical transducer and the hemoglobin transducer.
The*CELL-DYN 3000 uses an impedance transducer to count red blood cells and platelets. Figure 2 illustrates the principle of impedance cell counting and sizing. The principle is based on the measurement of changes in electrical resistance produced by a particle 18 as it passes through a small aperture 20. As each cell traverses the aperture 20, in the direction shown by arrow 21, the electrical resistance of the path between the * denotes trade mark
- 12 - P6001 submerged electrodes 22 and 24, (in this instance electrode 22 is negatively charged, and electrode 24 is positively charged) which are located on either side of the aperture 20, increases. The number of pulses is indicative of cell count, whilst the amplitude of the pulse is related to cell volume. Frequency distributions of pulse amplitude constitute volume histograms. These histograms are used to obtain red blood cell and platelet parameters such as MCV (mean cell volume) and RDW (red cell distribution width).
In the *CELL-DYN 3000 the impedance aperture 20 is 60 ~m in diameter and 70 ~m in length.
The*CELL-DYN 3000 uses an optical transducer to measure the light scattering characteristics of white blood cells. The transducer 26 is shown diagrammatically in Figure 3. A suspension of blood in which the red blood cells have been lysed is propelled at low velocity from the sample nozzle 28 (of around 160 microns diameter) where it comes into contact with a fast moving, laminar flow, sheath stream 30. In a process known as hydrodynamic focusing, the sample stream is attenuated to a central core 32. In the fused silica flow cell this core is 25-30 ~m in diameter. This arrangement ensures that usually only a single white blood cell is in the sensing region at any time and therefore coincidence problems are minimised. In addition, since the physical aperture is large (250 ~m square) the flow cell 34 is unlikely to clog, yet it still gives the resolution of a much smaller transducer.
A brief description of the *CELL-DYN3000 optical bench will be presented here to facilitate understanding the functioning of the white blood cell measurement * denotes trade mark
- 13 -process. A diagrammatic plan of the *CELL-DYN 3000 optical bench is shown in Fig. 4. Light source 40 is a polarised 5 mW helium°neon laser of wavelength 632.8 nm. The laser head is orientated so that the plane of polarisation is vertical. The laser beam is shaped and focused by front surface mirror 42, cylindrical lens 44, front surface mirror 46, vertical slit 48 (125 microns wide), and laser focusing lens 50 so that in the region of the central core 52 (a fused silica flow cell with a 250 micron square channel) of the sample stream the beam intensity profile in vertical plans is Gaussian with a ("one over a squared") diameter of about 70 um. In the horizontal plane the profile shows a "top hat" appearance, with the flattened top being about 80 um. This arrangement ensures that the instrument will continue to give reliable data even when the sample core wanders slightly from its normal position.
A white cell entering the focused laser beam will scatter light in all directions. Since the wavelength of the light is small compared with the cell size, this scattering phenomenon is described by Mie theory. Only part of the scattered light is collected by four photodetectors. Two silicon photodiodes 54 and 56 measure light scattered at half angles of about 1-3 degrees and about 3-10 degrees with respect to the laser beam. These photodiodes 54 and 56 are termed the "0 degree" and "l0 degree" detectors, respectively. Direct laser light is blocked with the observation bar 58. Light scatter at these low angles is some complex function of cell size.
Light scattered at 90 degrees to the laser beam is also collected using two photomultipliers 60 and 62 (PMTs).
* denotes trade mark
- 14 - P6001 PMTS, not photodiodes, are used in the 90 degree channel because relatively little light is scattered at high angles. One of the PMTS 62 has a horizontal polarises 61 in front of it. Since this will prevent vertically polarised light from striking the photocathode, any light detected by the "90 degree" depolarized PMT 62 is light that has been depolarised by its interaction with the white blood cell. The second photomultiplier 60 termed the "90 degree" PMT receives light reflected off a coverglass beamsplitter 63 angled at 45 degrees. The major proportion of this light is still vertically polarised.
The objective lens 64 and scatter stop 66 complete the orthogonal scatter channels. The low angle scatter channels also include a perforated mirror 70.
Data from the four photodetectors is used to construct a pair of scattergrams representative sample being shown in Figures 5 to 8. White blood cells can thus be separated into five subpopulations solely on the basis of light scatter.
For the red blood cell analysis, hemoglobin is converted to a heme-cyanide complex and measured by determination of absorbance at 550 nm in a 1 cm pathlength flow cell.
In the *CELL-DYN 3000, whole blood (120 ~L, open tube;
250 ~L closed tube) is aspirated via the specimen probe or cap pierces into a shear valve that isolates three precise aliquots. These aliquots are diluted with the appropriate diluent reagents and moved towards the transducers. At present, we use a diluent having the following composition in an aqueous solution: NaCl, 7.9 g/L, KCL, 0.4 g/L, * denotes trade mark f~f~f~~~~
- 15 - P6001 NaH2P04, 0.2 g/L, Na2HP04, 1.9 g/L, Na2EDTA, 0.3 g/L, NaF, 0.4 g/L, 2-phenoxyethanol 3m1/L and water to make 1 litre.
The diluent has pH 7.4 ~ 0.05, and an osmolality of 340 -1 3 mohs. A 32 ~L segment is sheared and diluted 250 times with the lytic agent of the present invention and transported to the optical transducer for determination of the white blood cell count and leukocyte differential. A
12 ~tL segment is sheared, diluted 250 times with hemoglobin reagent and transported to the hemoglobin transducer. The hemoglobin reagent is a mixture of a quaternary ammonium salt/~GCN solution with the diluent noted above. In the best mode, the quaternary ammonium salt solution consists of tetradecyltrimethylammonium bromide 90 g/L and potassium cyanide 0.75 g/L, mixed into 1 litre of deionized water. Then, 1 litre of the quanternary ammonium salt solution is mixed with 11 litres of the diluent described above. Finally, Triton X-114 is added at a concentration of 0.25 mL/L. A 0.8 ~aL segment is diluted 12,500 times with red blood cell diluent and transported to the impedance transducer for measurement of red blood cells and platelets.
Each pulse resulting from a particle passing through the sensing zone is amplified and compared to internal reference voltages. In this way, white blood cells are discriminated from red blond cell stroma and platelets in the white blood cell channel. In a similar manner, red blood cells and platelets axe discriminated in the red blood cell/platelets channel.
Ta make absolute blood cell counts, the volume of diluted blood passing through the transducer during data acquisition must be known. Far the red blood cell/platelet channel, this is achieved using a metering tube. During each count cycle, as cells are drawn through
- 16 - P6001 the impedance aperture, fluid is drawn through the metering tube. As the reagent meniscus passes an optical detector, the count cycle is started. The count cycle is stopped when the meniscus passes a second optical detector, after exactly 200 ~L of diluted blood has passed through the transducer. The count time can be used to detect debris in the orifice, since such material will reduce the effective aperture and increase count time.
This debris might adversely affect sizing data.
In the white blood cell channel, fluid metering is done using a syringe pump. Since the narrowest passageways in the white blood cell channel are relatively large (sample nozzle, 160 ;tm diameter; fused silica flow cell, 250 ~,m square), debris accumulation is much less likely to occur.
It is possible that more than one cell particle may be present simultaneously in the sensing zone during counting. If ignored, this coincidence will artificially reduce the cell count. Coincidence is directly related to the effective volume of the orifice and cell concentration and can therefore be corrected for mathematically. This is performed automatically for each white blood cell, red blood cell and platelet count.
*CELL-DYN 3000 automatically displays all numeric and graphic data after each measurement cycle. Specimen measurements are performed by selecting the run mode. The specimen may be identified as any one of five types, namely: patient, low control, normal control, high control, replicate. Operator ID, data, time, etc may be entered via the keyboard. Displayed data may be printed on 2-fold paper (8.5" x 11") via a graphics printer, a * deaotes trade mark
- 17 - P6001 single report to the page. A multicopy ticket report can also be printed via an optional ticket printer.
Numeric data for the current 1,000 cycles is automatically stored on the PC hard disk. This data log may be reviewed or printed as required. Each data file includes a sequence number, specimen type, specimen ID
if used, numeric data for all selected parameters, date, time and operator ID.
Using the setup mode, the user may set limits for any numeric data. Any data falling outside these limits are displayed in inverse on the video screen and are printed in bold type. When histogram data for platelets, or scattergram data for white blood cells do not meet certain criteria, each affected area is flagged with a region alert.
At the completion of each measurement cycle, the results are displayed on the monitor. Light scatter data from white blood cells are displayed as a pair of scattergrams. The absolute white blood cell count is displayed in units of thousands/~L of whole blood. The red blood cell data is displayed as a volume frequency distribution histogram with the abscissa calibrated in femtolitres. The absolute red blood cell count is displayed in units of millions/~L of whole blood.
Platelet data is displayed as a volume frequency distribution histogram with the abscissa in femtolitres.
The absolute platelet count is reported in units of thousands/uL of whole blood.
The *CELL-DYN 3000 measures hemoglobin as a hemecyanide complex. The hemoglobin reagent is an alkaline solution of a cationic detergent and potassium * denotes trade mark
- 18 - P6001 cyanide. The detergent lyses red blood cells causing hemoglobin release. At high pH, the hemoglobin releases heme chromophores which react with the cyanide present to form a stable complex. This is measured by its absorbance at 540 nm against a reagent blank. The hemoglobin result is reported in terms of its concentration in whole blood.
The user may select any of the following units: g/dL, g/L.
CELL-DYN 3000 determines mean cell volume (MCV) from the red blood cell size distribution. The result is reported directly in femtolitres. The hematocrit (HCT) is calculated from the red cell count and MCV as follows:
HCT = (RBC count x MCV)/10 The result is reported as percent packed red cells or as the proportion of packed red cells per unit volume of whole blood: L/L.
Red cell distribution width (RDW) is determined from the red cell volume distribution. It is simply the cv of the peak, expressed as percent [cv = (sd/mean) x 100].
This parameter is an index of red cell heterogeneity. The RDW increases with the degree of anisocytosis seen on the blood smear. Diagnostically useful information may be obtained by reviewing both MCV and RDW.
The five-part white blood cell differential is determined solely on the basis on light scatter. Since no cytochemical staining is required, the *CELL-DYN3000 realises an extremely high throughput (CBC/PLTs/WBC diff at a rate of 109/hour). The lytic agent of the present invention lyses red blood cells instantly, but does not affect the light scattering characteristics of white blood * denotes trade mark
- 19 - P6001 cells within the relevant measurement time. Data on the scatter characteristics of each white cell is obtained from four photodetectors. The "0 degree" detector collects light scattered at a half angle of about 1-3 degrees to the laser beam. The "10 degree" detector collects light scattered at a half angle of about 3-10 degrees. Scatter at low angles such as these is a function of cell volume. Scatter at high angles, such as perpendicular to the laser beam is function of the total amount of structure in the cell; its "structuredness".
All other things being equal, the high angle scatter of a cell will increase as, for example, the lobulation of the nucleus increases or as cytoplasmic granulation increases.
The CELL-DYN 3000 uses two photomultiplier tubes to collect "90 degree" scatter and "90 degree depolarised"
light scatter. In our application, at least, this depolarisation signal results from multiscattering phenomena within the white blood cells. It is not an artifact of cross depolarisation or autofluorescence.
Clinical usefulness of these new parameters - mean platelet volume [MPV], platelet distribution width [PDW]
and plateletcrit [PCT] has not yet been established.
Controversy exists regarding published findings.
Currently in the US, FDA regulations prohibit the reporting of these parameters until clinical utility is established. Elsewhere, these results can be reported, as required. If MPV data is required, it is strongly recommended that specimens should be at least one hour after collection, by which time the MPV will have stabilised. Generally, for about the first hour after collection into EDTA, MPV is increasing.
The *CELL-DYN3000 calculates MPV from the platelet histogram, to which a log-normal curve has been fitted.
* denotes trade mark - ~0 - P6001 This parameter is reported directly in femtolitres. PCT
is calculated from the platelet count and MPV as follows:
PCT = (PLC.' x MPV) /10 The result is reported as percent or in mL/L. The PDW is the geometric s.d. of the platelet size distribution. Tt is derived from the platelet histogram data and reported as 10(g.s.d).
These red cell indices are useful indications of red blood cell morphology and are useful in the classification of anemias. Tn addition, the index data for a particular specimen or collection of specimens, is very stable and should not change significantly over the long term, even though the values used to calculate each may have altered significantly. Because of this stability, the red blood cell indices may be used to quality control instrument performance. Gull°s moving average QC program utilises this principle.
Mean cell hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) whenever appropriate are parameters that are measured. The following equations apply:
MCH = (HGH/RBC count) x 10 MCHC -- (HGH/HCT) x 10 MCH is reported in picograms or femtomoles. MCHC is reported as g/L, g/dL or mM/L.
21 - 1~60U1 ~teferring to Figure 5, scattergrams are shown illustrating laser light scattering properties of whole blood from a normal donor after admixture with lytic agent described herein.
Scatterarams 5a, 6a ' 7a. 8a y axis: 0 degree scatter x axis: 10 degree scatter Scatterg~rams 5b, 6c,, 7c< 8c y axis: 90 degree scatter x axis: 90 degree depolarised scatter Sub,populations 1 = lymphocytes, ~ = basophils, 3 = monocytes, 4 = neutrophils and eosinophils, 5 = neutrophils, 6 = eosinophils.
This patient sample was selected because it had elevated levels of monocytes and eosinophils. Previously, these samples were not easily differentiated into five subpopulations because it was difficult to separate and enumberate lymphocytes and monocytes. using the same axes information as discussed with respect to Example 1, Figure 5, regions 5 and 6 of Figure 6 show the enumeration of neutorophils and eisonophils, respectively.
This patient sample was also selected because it had elevated levels of monocytes and eosinophils. Using the same axes information as discussed with respect to Example 1, Figure 5, regions 5 and 6 of Figure 7 show the enumeration of neutorophils and eisonophils, respectively.
This sample was also selected because it had elevated levels of monocytes and eosinophils. Using the same axes information as discussed with respect to Example 1, Figure 5, regions 5 and 6 of Figure 8 show the enumeration of neutorophils and eisonophils, respectively.
While certain representative embodiments and details have been shown for the purpose of illustrating the invention, various changes and modifications can be made therein without departing from the scope of the invention as defined in the appended claims.
Technical Data for Figure 6 Specimen 1D:
Type: File 3 Open Sample Mode WBC: 6.4 K/uL Immature granulocyte:0.1 LYM: 0.8 13.0%L Incomplete lysis %: 4.8 NEU: 4.9 75.7%N Gran CV in 10D perm: 12.1 MONO: 0.6 8.6%M RBC upr menis time: 3885 EOS: 0,2 2.4%E RBC count time: 7085 BASO: 0.0 0.4%B
RBC: 5.21 M/uL
HGB: 15.5 g/dt HCT: 50.6%
MCV: 97.1 fL
MCH: 29.7 pg MCHC: 30.6 g/dl RDW: 12.9%
PLT: 250, K/u1 MPV: fl 6.9 PCT: % 0.17 PDW: 10(GSD) 16.9 xe Figure 6a x - 10 D Figure 6c x - 90 D
y - 0 D y - 90 DEP
Figure 6b x - PLT Figure 6d x - RBC
y - number y - number o~~"~a~i~~~~
Technical Data for Figure 7 SpecimenID: 7127 Immature granulocyte:0.1 Type: PATIENT Incomplete lysis 2.1 %:
Open Gran CB in 10D parm:12.3 Sample Mode RBC upr menis time: 3970 RBC count time: 7080 WBC: 8.3 K/ul LYM: 0.7 8.3%L
I~'EU: 6.5 77.5%Id MONO: 0.8 10.1%M
EDS: 0.3 3.5%E
BASO: 0.1 0,5%B
RBC: 4.12 M/ul HGB: 11.7 g/dl HCT: 38.6%
MCV: 93.7 fL
MCH: 28.5 pg MCHC: 30.4 g/d1 RDW: 16.0%
PLT: 116 K/ul MPV: fl 7.2 PCT: % 0.08 PDW: 10 (GSD) 16.9 xes Figure 6a x - 10 D Figure 6b x - PLT
y - 0 D y - number Figure 6c x - 90 D Figure 6d x - RBC
y - 90 DEP y - number ~:~~~':~.~
-- 25 - P60o1 Technical Data for Figure 8 Specimen Immature granulocyte: 0.0 ID:
Type:File 1 Incomplete lysis %: 2.2 OpenSample Mode Gran CV in 10D perm: 11.7 RBC upr mania time: 3905 IiBC count time: 7070 WBC:7.4 K/ul LYM:0.5 6.6%L
NEL1:5. 9 79 > 5%N
RBC:5.14 M/ul HGB:13.8 g/dl HCT:46.1 %
MCV:89.6 fl MCH:26.9 pg MCHC:30.0 g/dl RDW:15.7%
PLT:394 K/ul MPV f i 7 . 2 :
PCT:% 0.28 PDW:10 (GSD) 16.7 Axes Figure 6a x ° 10 D Figuxe 6c x ° 90 D
y - 0 D y - 90 DEP
Figure 6b x - PLT Figure 6d x - RBC
y ° number y - number
(a) an aromatic oxyethanol used in a concentration sufficient to impart leukoprotective properties to said flow cytometry lytic agent;
(b) an organic buffer with pK at or near 8.5 serving to provide pH
buffering capacity and to increase the electrical conductivity of the lytic agent; and (c) a non-ionic detergent component.
(a) contacting a whole blood sample containing red blood cells and leukocytes with a diluent;
(b) lysing said red blood cells and sheathing said leukocyte cells by the addition of a flow cytometry lytic agent to said diluted whole blood sample, said flow cytometry lytic agent consisting essentially of:
(1) an aromatic oxyethanol used in a concentration sufficient to impart leukoprotective properties to said flow cytometry lytic agent;
(2) an organic buffer with pK at or near 8.5 serving to provide pH
buffering capacity and to increase the electrical conductivity of the lytic agent; and (3) a non-ionic detergent component;
(c) intersecting said lysed red blood cells and said sheathed leukocytes with a focused laser beam;
(d) measuring four light scattering parameters resulting from said intersection at:
(1) 0 degree light scatter;
(2) 10 degree light scatter;
(3) 90 degree light scatter;
(4) 90 degree depolarized light scatter; and (e) resolving the measured light scattering parameters to obtain a five subpopulation differential enumerating the neutrophils, lymphocytes, monocytes, eosinophils and basophils.
Priority Applications (2)
|Application Number||Priority Date||Filing Date||Title|
|Publication Number||Publication Date|
|CA2016699A1 true CA2016699A1 (en)||1990-11-15|
|CA2016699C true CA2016699C (en)||2003-11-18|
Family Applications (1)
|Application Number||Title||Priority Date||Filing Date|
|CA 2016699 Expired - Lifetime CA2016699C (en)||1989-05-15||1990-05-14||Lytic agents and uses thereof|
Country Status (6)
|US (1)||US5510267A (en)|
|EP (1)||EP0398652B1 (en)|
|JP (1)||JPH0726956B2 (en)|
|CA (1)||CA2016699C (en)|
|DE (2)||DE69011198D1 (en)|
|ES (1)||ES2060949T3 (en)|
Families Citing this family (73)
|Publication number||Priority date||Publication date||Assignee||Title|
|EP0626067A4 (en) *||1992-02-07||1997-06-25||Abbott Lab||Method for accurately enumerating and sensitively qualifying heterogeneous cell populations in cytolytic processing conditions.|
|US6509192B1 (en) *||1992-02-24||2003-01-21||Coulter International Corp.||Quality control method|
|EP0582736A1 (en) *||1992-08-11||1994-02-16||Abbott Laboratories||Flow cytometry sheath reagent for elimination of red cells with preservation of nucleated cells|
|EP0598663B1 (en) *||1992-11-19||2000-02-02||Sysmex Corporation||A pretreatment method for blood analysis|
|US6812032B1 (en)||1993-01-21||2004-11-02||Cdc Technologies, Inc.||Apparatus and method for making a plurality of reagent mixtures and analyzing particle distributions of the reagent mixtures|
|JP3355038B2 (en) *||1994-08-03||2002-12-09||シスメックス株式会社||Leukocyte classification method|
|FR2733835B1 (en) *||1995-05-03||1997-07-18||Hycel Groupe Lisabio||Method and device for detecting the red blood cell lysis point|
|US5639630A (en) *||1995-05-16||1997-06-17||Bayer Corporation||Method and reagent composition for performing leukocyte differential counts on fresh and aged whole blood samples, based on intrinsic peroxidase activity of leukocytes|
|JP2000502446A (en) *||1995-12-18||2000-02-29||センター フォー ラボラトリー テクノロジー，インク．||Blood diagnostic apparatus and determination method|
|US5817518A (en) *||1995-12-18||1998-10-06||Coulter International Corp.||Reagent and method for differential determination of leukocytes in blood|
|US6025201A (en) *||1995-12-28||2000-02-15||Bayer Corporation||Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples|
|US5817519A (en) *||1995-12-28||1998-10-06||Bayer Corporation||Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples|
|US5874310A (en) *||1997-11-21||1999-02-23||Coulter International Corp.||Method for differentiation of nucleated red blood cells|
|US5917584A (en) *||1997-11-21||1999-06-29||Coulter International Corp.||Method for differentiation of nucleated red blood cells|
|US6304328B1 (en) *||1998-08-14||2001-10-16||Research Foundation Of State University Of New York, The Office Of Technology Licensing, Suny||Non-contact temperature and concentration measurement on liquid surfaces|
|US6067157A (en) *||1998-10-09||2000-05-23||University Of Washington||Dual large angle light scattering detection|
|US6423505B1 (en)||1998-12-03||2002-07-23||Becton Dickinson And Company||Methods and reagents for quantitation of HLA-DR and CD11b expression on peripheral blood cells|
|US6200766B1 (en)||1998-12-03||2001-03-13||Becton Dickinson And Company||Methods and reagents for quantitation of HLA-DR expression on peripheral blood cells|
|US6214625B1 (en) *||1999-04-28||2001-04-10||Coulter International Corp.||Composition and method for differentiation of basophils and eosinophils in blood|
|US6210969B1 (en) *||1999-04-28||2001-04-03||Coulter International Corp.||Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood|
|US6232125B1 (en)||1999-08-09||2001-05-15||Coulter International Corp.||Method and apparatus for differentiating and enumerating leukocytes|
|US6784981B1 (en) *||2000-06-02||2004-08-31||Idexx Laboratories, Inc.||Flow cytometry-based hematology system|
|US7420659B1 (en) *||2000-06-02||2008-09-02||Honeywell Interantional Inc.||Flow control system of a cartridge|
|US20060263888A1 (en) *||2000-06-02||2006-11-23||Honeywell International Inc.||Differential white blood count on a disposable card|
|US7630075B2 (en) *||2004-09-27||2009-12-08||Honeywell International Inc.||Circular polarization illumination based analyzer system|
|JP5431732B2 (en) *||2005-12-29||2014-03-05||ハネウェル・インターナショナル・インコーポレーテッド||Assay implementation in a microfluidic format|
|US7061595B2 (en) *||2000-08-02||2006-06-13||Honeywell International Inc.||Miniaturized flow controller with closed loop regulation|
|US7471394B2 (en) *||2000-08-02||2008-12-30||Honeywell International Inc.||Optical detection system with polarizing beamsplitter|
|US7277166B2 (en) *||2000-08-02||2007-10-02||Honeywell International Inc.||Cytometer analysis cartridge optical configuration|
|US7630063B2 (en) *||2000-08-02||2009-12-08||Honeywell International Inc.||Miniaturized cytometer for detecting multiple species in a sample|
|WO2002099800A1 (en)||2001-06-01||2002-12-12||Fujitsu Limited||Magneto-optic recording medium device|
|US6869798B2 (en) *||2003-04-17||2005-03-22||Clinical Diagnostics Solutions, Inc.||Lytic reagent composition for leukocyte differential analysis|
|WO2007075922A3 (en) *||2005-12-22||2007-09-27||Ron L Bardell||Portable sample analyzer cartridge|
|US7641856B2 (en) *||2004-05-14||2010-01-05||Honeywell International Inc.||Portable sample analyzer with removable cartridge|
|EP3121601A1 (en) *||2005-12-22||2017-01-25||Honeywell International Inc.||Portable sample analyzer system|
|US8071051B2 (en) *||2004-05-14||2011-12-06||Honeywell International Inc.||Portable sample analyzer cartridge|
|JP5175213B2 (en) *||2005-12-22||2013-04-03||ハネウェル・インターナショナル・インコーポレーテッド||Portable sample analysis system|
|US7242474B2 (en) *||2004-07-27||2007-07-10||Cox James A||Cytometer having fluid core stream position control|
|US8329118B2 (en)||2004-09-02||2012-12-11||Honeywell International Inc.||Method and apparatus for determining one or more operating parameters for a microfluidic circuit|
|US20060179731A1 (en) *||2004-11-02||2006-08-17||Purvis Harrison G||Temporary railing for a building including access opening and associated methods|
|FR2883972B1 (en) *||2005-03-31||2007-11-16||C2 Diagnostics Sa||Process for the analysis of a blood sample and reagent and device for its implementation|
|EP1875200A1 (en)||2005-04-29||2008-01-09||Honeywell International Inc.||Cytometer cell counting and size measurement method|
|WO2007005974A3 (en) *||2005-07-01||2007-06-14||Cleopatra Cabuz||A flow metered analyzer|
|JP4995197B2 (en) *||2005-07-01||2012-08-08||ハネウェル・インターナショナル・インコーポレーテッド||Molding a cartridge having a 3d hydrodynamic focusing|
|EP1901846B1 (en) *||2005-07-01||2015-01-14||Honeywell International Inc.||A microfluidic card for rbc analysis|
|US7843563B2 (en) *||2005-08-16||2010-11-30||Honeywell International Inc.||Light scattering and imaging optical system|
|US7806604B2 (en) *||2005-10-20||2010-10-05||Honeywell International Inc.||Face detection and tracking in a wide field of view|
|US7674622B2 (en) *||2006-12-22||2010-03-09||Abbott Laboratories, Inc.||Method for determination of nucleated red blood cells and leukocytes in a whole blood sample in an automated hematology analyzer|
|US7449337B2 (en) *||2007-01-24||2008-11-11||Idexx Laboratories, Inc.||Lytic reagent and method for leukocytes differential in whole blood|
|US7816135B2 (en)||2007-07-05||2010-10-19||Becton, Dickinson And Company||Method of analyzing lymphocytes|
|CN101349644B (en) *||2007-07-20||2012-06-27||深圳迈瑞生物医疗电子股份有限公司||Leukocytes classification agent and use method thereof|
|US8102161B2 (en) *||2007-09-25||2012-01-24||Tdk Corporation||Stable output in a switching power supply by smoothing the output of the secondary coil|
|JP2009083382A (en) *||2007-10-01||2009-04-23||Brother Ind Ltd||Image forming device and image processing program|
|CN101470108B (en)||2007-12-24||2013-11-27||深圳迈瑞生物医疗电子股份有限公司||Reagent and method for classifying leukocyte|
|CN101475754A (en) *||2008-01-04||2009-07-08||深圳迈瑞生物医疗电子股份有限公司||Asymmetric cyanine fluorochrome composition and use in biological sample dyeing|
|EP2247746A4 (en) *||2008-01-31||2012-08-01||Amyris Inc||Methods of monitoring metabolic pathways|
|JP2009236798A (en) *||2008-03-28||2009-10-15||Sysmex Corp||Method for classifying and counting basophils|
|CN104965068B (en) *||2008-05-09||2017-12-08||希森美康株式会社||Blood analyzer, a blood analysis method and a hemolytic agent|
|CN101602762B (en) *||2008-06-10||2013-10-16||深圳迈瑞生物医疗电子股份有限公司||Asymmetric cyanine compound, preparation method and application thereof|
|US20100034704A1 (en) *||2008-08-06||2010-02-11||Honeywell International Inc.||Microfluidic cartridge channel with reduced bubble formation|
|US8037354B2 (en)||2008-09-18||2011-10-11||Honeywell International Inc.||Apparatus and method for operating a computing platform without a battery pack|
|CN101726579B (en) *||2008-10-17||2014-06-18||深圳迈瑞生物医疗电子股份有限公司||Blood test reagent and method|
|US8367358B2 (en) *||2008-12-17||2013-02-05||Shenzhen Mindray Bio-Medical Electronics Co., Ltd.||Reagent, kit and method for differentiating and counting leukocytes|
|CN101988082B (en) *||2009-07-31||2015-04-08||深圳迈瑞生物医疗电子股份有限公司||Leukocyte classified counting reagent, kit and preparation method thereof and method of leukocyte classified counting|
|JP4907705B2 (en) *||2009-09-29||2012-04-04||シスメックス株式会社||Red blood cell analysis reagents in the urine|
|US9091677B2 (en)||2010-08-09||2015-07-28||Beckman Coulter, Inc.||Isotonic buffered composition and method that enables counting of cells|
|US8741233B2 (en)||2011-12-27||2014-06-03||Honeywell International Inc.||Disposable cartridge for fluid analysis|
|US8741234B2 (en)||2011-12-27||2014-06-03||Honeywell International Inc.||Disposable cartridge for fluid analysis|
|US8741235B2 (en)||2011-12-27||2014-06-03||Honeywell International Inc.||Two step sample loading of a fluid analysis cartridge|
|US8663583B2 (en)||2011-12-27||2014-03-04||Honeywell International Inc.||Disposable cartridge for fluid analysis|
|EP2972321A4 (en) *||2013-03-12||2016-11-02||Abbott Lab||Reagents, systems and methods for analyzing white blood cells|
|WO2015073952A1 (en) *||2013-11-15||2015-05-21||University Of Maryland||Integrated and standalone label and reagent-free microfluidic devices and microsystems for differential white blood cell counts|
|EP3114926A1 (en)||2015-07-10||2017-01-11||Marine harvest Norway AS||Device and method for removing parasites on fish|
Family Cites Families (22)
|Publication number||Priority date||Publication date||Assignee||Title|
|US3874852B1 (en) *||1974-07-05||1989-07-11|
|US3962125A (en) *||1975-01-13||1976-06-08||Coulter Diagnostics, Inc.||Multi-purpose diluent for use in blood analysis by electronic instrumentation of the coulter type|
|US4185964A (en) *||1977-02-08||1980-01-29||Central Laboratories of Associated Maryland Pathologists, Ltd.||Lysing reagent|
|US4099917A (en) *||1977-07-21||1978-07-11||Technicon Instruments Corporation||Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles|
|US4577964A (en) *||1978-09-06||1986-03-25||Ortho Diagnostics, Inc.||Apparatus and method for detecting platelets in whole blood|
|US4284412A (en) *||1979-07-13||1981-08-18||Ortho Diagnostics, Inc.||Method and apparatus for automated identification and enumeration of specified blood cell subclasses|
|US4286963A (en)||1979-11-23||1981-09-01||Coulter Electronics, Inc.||Differential lymphoid-myeloid determination of leukocytes in whole blood|
|US4465774A (en) *||1981-07-16||1984-08-14||Sherwood Medical Company||Standard or control material for glysocylated or total hemoglobin determination|
|US4506018A (en) *||1982-12-30||1985-03-19||Becton, Dickinson And Company||Blood diluent|
|US4485175A (en) *||1983-01-03||1984-11-27||Coulter Electronics, Inc.||Method for three-volume differential determination of lymphocyte, monocyte and granulocyte populations of leukocytes|
|US4743678A (en) *||1983-04-27||1988-05-10||President And Fellows Of Harvard College||Method and products for detection of human T cell leukemia virus|
|US4637986A (en) *||1983-08-22||1987-01-20||Ortho Diagnostic Systems, Inc.||Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC count|
|JPH0333230B2 (en) *||1983-09-29||1991-05-16||Toa Medical Electronics|
|US4654312A (en) *||1984-05-14||1987-03-31||Becton, Dickinson And Company||Lysing agent for analysis of peripheral blood cells|
|US4902613A (en) *||1984-05-14||1990-02-20||Becton, Dickinson And Company||Lysing agent for analysis of peripheral blood cells|
|US4751179A (en) *||1984-05-31||1988-06-14||Coulter Electronics, Inc.||Method and reagents for differential determination of four populations of leukocytes in blood|
|US4727020A (en) *||1985-02-25||1988-02-23||Becton, Dickinson And Company||Method for analysis of subpopulations of blood cells|
|US4745071A (en) *||1985-09-05||1988-05-17||Sequoia-Turner Corporation||Method for the volumetric differentiation of blood cells types|
|NL8601000A (en) *||1986-04-21||1987-11-16||Jan Greve T H Twente Afdeling||The use of polarized light in flow cytometry.|
|US5039613A (en) *||1986-11-27||1991-08-13||Toa Medical Electronics Co., Ltd.||Reagents used in a method of classifying leukocytes by flow cytometry|
|JPH0635972B2 (en) *||1986-11-27||1994-05-11||東亜医用電子株式会社||Flow - cytometry - of by the white blood cell classification method|
|JPH0782010B2 (en) *||1987-10-16||1995-09-06||東亜医用電子株式会社||Particle analyzer sheath liquid|
Also Published As
|Publication number||Publication date||Type|
|US5616501A (en)||Reticulocyte analyzing method and apparatus utilizing light scatter techniques|
|US5518928A (en)||Leukocyte differentiation method|
|US5389549A (en)||Method for classifying leukocytes and a reagent used therefor|
|US5316951A (en)||Method for the improved determination of white blood cell subpopulations|
|US5227304A (en)||Method for counting whole blood diluent and detergent reagent system|
|US3710933A (en)||Multisensor particle sorter|
|US6646742B1 (en)||Optical device and method for multi-angle laser light scatter|
|US5817519A (en)||Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples|
|US5798827A (en)||Apparatus and method for determination of individual red blood cell shape|
|Bain et al.||Basic haematological techniques|
|US5812419A (en)||Fully automated analysis method with optical system for blood cell analyzer|
|US20050219527A1 (en)||Sample analyzer and computer program product|
|US5434081A (en)||Method of classifying leukocytes by flow cytometry|
|US5874310A (en)||Method for differentiation of nucleated red blood cells|
|US6025201A (en)||Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples|
|US6127184A (en)||Calibration of a whole blood sample analyzer|
|US5116539A (en)||Reagent and method for measuring leukocytes and hemoglobin in blood|
|US6067157A (en)||Dual large angle light scattering detection|
|Walters et al.||Performance evaluation of the Sysmex XE-2100 hematology analyzer|
|US5316725A (en)||Reagent system for the improved determination of white blood cell subpopulations|
|US6784981B1 (en)||Flow cytometry-based hematology system|
|US5631165A (en)||Method for performing automated hematology and cytometry analysis|
|US5656499A (en)||Method for performing automated hematology and cytometry analysis|
|US6410330B1 (en)||Method for measurement of nucleated red blood cells|
|US5691204A (en)||Compositions and methods for the rapid analysis of reticulocytes|
Effective date: 20121202